Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Potentially causes in Embolic Stroke of Undetermined Source
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
150
To describe the prevalence and degree of overlap of Potentially Embolic Source (PES) in Embolic Stroke of Undetermined Source (ESUS) patients
Multiple secondary prevention trials comparing direct anticoagulants against aspirin have been performed in ESUS population, with negative results. One explanation is that etiological subtypes of ESUS, called PES are numerous and can coexist in the same patient
Electronic medical records of patients admitted to the Stroke Unit between June 2015-June 2020 were analyzed. In those that met ESUS criteria the following variables were collected: cardiovascular risk factors, initial/discharge NIHSS, reperfusion treatment, discharge modified Rankin Scale (mRS) and intrahospital mortality. According to Ntaios G, et al., PES was defined as: atrial heart disease; atheromatous disease; ventricular pathology; valvular disease; cancer; permeable oval foramen
Out of 389 ischemic strokes, 54 (13.8%) met ESUS criteria. The most common risk factor was high blood pressure (72%), dyslipidemia (38.8%) and ischemic heart disease (24%). The initial NIHSS was 4 (RIC 1-5) and at discharge 1 (RIC 1-3.75). Discharge mRS scored 1 (RIC 0-3). No deaths were recorded. PES and their frequency were: atheromatous disease 61.11%; atrial hearth disease 46.2%; valvular disease 27.7%; ventricular pathology 14.8%; permeable oval foramen 9.25% and cancer 3.7%. In 7 patients (12.9%) no PES was registered; 1 in 16 (29.6%); and 2 or more in 31 (57.4%)
In our study, most ESUS patients have two or more PES, as were described in other case series. We find atheromatous disease as the most common one, possibly in relation to a high proportion of patients with coronary history and atheromatous disease
Authors/Disclosures
Franco E. Appiani, MD (ACE Alzheimer Cente - Instituto Catalán de Neurociencias Aplicadas)
PRESENTER 		Dr. Appiani has nothing to disclose.
No disclosure on file
Carla F. Bolano Diaz, MD (John Walton Muscular Dystrophy Research Centre) Dr. Bolano Diaz has nothing to disclose.
Guido D. Vazquez II, PhD (Neurociencias Favaloro) Dr. Vazquez has nothing to disclose.
santiago Claverie santiago Claverie has nothing to disclose.
No disclosure on file